Skip to main content
. 2018 Mar 5;73(6):1586–1594. doi: 10.1093/jac/dky033

Figure 1.

Figure 1.

SCH79797 significantly improves survival, lung injury and inflammation in murine E. coli pneumonia. SCH79797 at 10 μM was determined to be the most effective dose when given as a treatment 6 h after infection (a; n = 17–19 per group, *P < 0.05 for 10 μM SCH79797, SCH 10, versus PBS; 100μM SCH79797 (SCH 100) provided no survival advantage versus PBS). H&E staining of lungs demonstrated less lung injury in mice treated with SCH79797 10 μM (SCH) at 24 h post-infection (b and c; n = 3 lungs per group for lung injury score analysis, *P < 0.05 for SCH- versus PBS-treated groups, data as mean ± SD). BAL at 24 h showed reduced inflammatory cell influx (d), reduced bacterial burden (e) and a trend towards a reduction in both inflammatory cytokine levels (f) and vascular permeability (g) with SCH treatment (n = 6 per group for all analyses, *P < 0.05 and P = 0.16 for macrophage inflammatory protein-2 (MIP-2) concentrations and P = 0.055 for albumin concentrations, data as mean ± SD). This figure appears in colour in the online version of JAC and in black and white in the print version of JAC.